Search

Your search keyword '"Grimaldi, L. M. E."' showing total 124 results

Search Constraints

Start Over You searched for: Author "Grimaldi, L. M. E." Remove constraint Author: "Grimaldi, L. M. E."
124 results on '"Grimaldi, L. M. E."'

Search Results

1. Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

3. Signs and symptoms of COVID-19 in patients with multiple sclerosis

4. Cytokine Genes in Multiple Sclerosis

5. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

6. Signs and symptoms of COVID-19 in patients with multiple sclerosis

7. Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

8. Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group—Italian Neurological Society

10. Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

11. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

12. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

13. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study

18. Three years of experience: the Italian registry and safety data update

19. Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain: Abstracts of Symposia and free communications

20. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

21. Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

27. The Italian multiple sclerosis register

28. Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

29. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

30. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

31. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

32. Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.

35. Glucocorticoid-related genetic susceptibility for Alzheimer's disease

36. Reply

37. Induction of IL-1 receptor antagonist by interferon beta: implication for the treatment of multiple sclerosis

40. Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease

41. Safety and efficacy of natalizumab in children with multiple sclerosis

42. Three years of experience: the Italian registry and safety data update

Catalog

Books, media, physical & digital resources